Integrating evidence from multiple sources to evaluate post-approval safety: An example of sildenafil citrate and cardiovascular events

Current Medical Research and Opinion

Volumn 24, Issue 7, 2008, Pages 1861-1868

  Sobel, Rachel E ^a   Reynolds, Robert F ^a,b  

^a PFIZER INC   (United States)

^b TULANE UNIVERSITY   (United States)

Author keywords

Cardiovascular system; Drug toxicity; Epidemiologic studies; Erectile dysfunction; Phosphodiesterase inhibitors; Postmarketing; Product surveillance; Risk management; Sildenafil

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; SILDENAFIL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; DRUG FATALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ERECTILE DYSFUNCTION; FEMALE; HEALTH CARE PERSONNEL; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; DATABASES, FACTUAL; DRUG APPROVAL; DRUG TOXICITY; HUMANS; INCIDENCE; MALE; MYOCARDIAL INFARCTION; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; SULFONES; VASODILATOR AGENTS;

EID: 47949101669     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802128781     Document Type: Article

References (38)

1. Russell S. FDA posts web site on Viagra deaths - up to 16, but cause unclear. San Francisco Chronicle 1998 Wednesday, June 10;Sect. A-7
2. Braun M, Klotz T, Mathers M, et al. 'Viagra effect' - influence of mass media on patient behavior. Urol Int 2001;66:145-8
3. Rosen RC. Sildenafil: medical advance or media event? Lancet 1998;351:1599
4. Mitka M. Some men who take Viagra die - why? JAMA 2000;283:590-1
5. Schwartz J. Viagra's hidden risks. Washington Post 1998 Tuesday, June 9;Sect. Z12
6. Schwartz J. Deaths of 6 Viagra users studied. Washington Post 1998 Saturday, May 23;Sect. A02
7. US Food and Drug Administration. Pfizer updates Viagra labeling. November 24, 1998. Available at: http://www.fda.gov/bbs/topics/ANSWERS/ANS00926.html [Last accessed 18 March 2008]
8. Ahmad SR, Goetsch R, Marks N. Spontaneous reporting in the United States. In Strom BL, ed. Pharmacoepidemiology, 4th edn. Chichester, UK: John Wiley & Sons, 2005
9. Edwards I, Olsson S, Lindquist M, Hugman B. Global Drug Surveillance. The WHO Programme for International Drug Monitoring. In Strom BL, ed. Pharmacoepidemiology, 4th edn. Chichester, UK: John Wiley & Sons, 2005
10. US Food and Drug Administration. Guidance For Industry: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment, 2005. Available at: http://www.fda.gov/cber/gdlns/pharmacovig.htm [Last accessed 2 July 2007]
11. European Medicines Agency Committee for Medicinal Products for Human Use. Guideline on risk management systems for medicinal products for human use, 2005. Available at: http://www.emea.europa.eu/pdfs/human/euleg/9626805en.pdf [Last accessed 2 July 2007]
12. Weber JCP. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. In: Rainsford KD, Velo GP, eds. Advances in Inflammation Research. New York, NY: Raven Press, 1984:1-7
13. Hartnell NR, Wilson JP. Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy 2004;24:743-9
14. Hartnell NR, Wilson JP, Patel NC, et al. Adverse event reporting with selective serotonin-reuptake inhibitors. Ann Pharmacother 2003;37:1387-91
15. Wallenstein EJ, Fife D. Temporal patterns of NSAID spontaneous adverse event reports: the Weber effect revisited. Drug Saf 2001;24:233-7
16. Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther 1998;20(Suppl C):40-4
17. Kirby M, Jackson G, Betteridge J, Friedli K. Is erectile dysfunction a marker for cardiovascular disease? Int J Clin Pract 2001;55:614-18
18. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med 2007;120:151-7
19. Bacon CG, Mittleman MA, Kawachi I, et al. A prospective study of risk factors for erectile dysfunction. J Urol 2006;176:217-21
20. Thompson IM, Tangen CM, Goodman PJ, et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005;294:2996-3002
21. Mittleman MA, Maclure M, Lewis MA, et al. Cardiovascular outcomes among sildenafil users: results of the International Men's Health study. Int J Clin Pract 2008;62:367-73
22. Dow Jones & Company. Factiva Database. 2008; Available at: http://www.factiva.com/[Last accessed 13 March 2008]
23. Padma-Nathan H, Eardley I, Kloner RA, et al. A 4-year update on the safety of sildenafil citrate (Viagra®). Urology 2002;60(Suppl 2B):67-90
24. Data on file. Pfizer Inc, New York, NY, 2003. File PSUR-03-2003
25. Jackson G, Gillies H, Osterloh I. Past, present, and future: a 7-year update of Viagra* (sildenafil citrate). Int J Clin Pract 2005;59:680-91
26. Data on file. Pfizer Inc, New York, NY. 2007. File SCS-1.4.1-2007
27. International Conference on Harmonisation. MedDRA Coding Dictionary. Available at: http://www.meddramsso.com/MSSOWeb/index.htm [Last accessed 10 March 2008]
28. Meinzinger MM, Barry WS. Prospective study of the influence of the media on reporting medical events. Drug Inf J 1990;24:575-7
29. American Heart Association. Men and cardiovascular diseases: 2007 update. Available at: http://www.americanheart.org/presenter.jhtml?identifier=3000935 [Last accessed 2 July 2007]
30. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, et al. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999;353:1547-57
31. Williams D, Feely J. Initial uptake in use of sildenafil in general practice. Eur J Clin Pharmacol 2001;56:911-14
32. Shakir SAW, Wilton LV, Boshier A, et al. Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. BMJ 2001;322:651-2
33. Boshier A, Wilton LV, Shakir SA. Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999. BJU Int 2004;93:796-801
34. Marchione M. Diabetes Drug Side Effect Reports Triple. US News and World Report 2007. Available at: http://hosted.ap.org/dynamic/stories/D/ DIABETES_DRUG_RISKS?SITE=DCUSN&SECTION=HOME&TEMPLATE=DEFAULT [Last accessed 17 July 2007]
35. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
36. Rossi AC, Hsu JP, Faich GA. Ulcerogenicity of piroxicam: an analysis of spontaneously reported data. Br Med J (Clin Res Ed) 1987;294:147-50
37. Waller PC, Arlett P. Responding to signals. In: Mann R, Andrews E, eds. Pharmacovigilance, 1st edn. Chichester, UK: John Wiley & Sons, 2002:105-28
38. US Food and Drug Administration. Adverse Event Reporting System (AERS). Available at: http://www.fda.gov/cder/aers/default.htm [Last accessed 13 March 2008]